Erasca and Tango Therapeutics to Evaluate Combination of ERAS-0015 and Vopimetostat in MTAPdel pancreatic or MTAPdel RASm NSCLC March 10, 2026
Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Ph 1b/2a Agent and Announces First Close of Seed Financing March 10, 2026
FAILED TRIAL: persevERA Breast Cancer study of giredestrant-palbociclib combo did not meet the primary objective of statistically significant PFS improvement in ER+ve, HER2-neg locally advanced or metastatic breast cancer March 10, 2026
Supplemental BLA for ANKTIVA + BCG in BCG-Unresponsive NMIBC with Papillary Disease Resubmitted to the FDA March 10, 2026
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program March 10, 2026
Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Ph 2 Results March 10, 2026
Enhertu granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2+ve early breast cancer March 10, 2026
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. March 10, 2026
Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine March 10, 2026
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8M March 10, 2026
Hopewell Therapeutics Announces Sublicense of Proprietary Lipid Nanoparticles for Novel Cancer Vaccine to Foxcroft Therapeutics March 10, 2026
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission March 10, 2026
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio March 10, 2026
Agreement Signed for Planning of Proposed Ph 3 Trial of Ampligen for Late-Stage Pancreatic Cancer March 10, 2026
Positive Ph 3 Results from SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma Announced March 10, 2026
FAILED TRIAL: Ph 3 Study of XOSPATA™ (gilteritinib) Did not Meet Primary Endpoint of OS in Patients with Newly Diagnosed FLT3m+ AML March 10, 2026
Full results from Ph 2 CHOPIN trial of percutaneous hepatic perfusion, ipilimumab, and nivolumab combo in metastatic uveal melanoma published in The Lancet Oncology March 10, 2026
Ph 2 SKNJCT-003 Trial Reported 73% Clinical Clearance and 40% Histological Clearance (CR) with D-MNA in BCC March 10, 2026
Positive CHMP opinion for Ojemda monotherapy for pediatric R/R BRAF-altered pediatric low-grade glioma March 10, 2026
